[Featured Stock] Nextbiomedical Rises on FDA Approval News for Endoscopic Hemostatic Agent

Nextbiomedical is showing strong performance. The news that its endoscopic hemostatic product received approval from the U.S. Food and Drug Administration (FDA) appears to have had an impact.

As of 1:30 PM on the 28th, Nextbiomedical was trading at 46,600 KRW, up 9,400 KRW (25.27%) from the previous trading day.

On this day, Nextbiomedical announced that its endoscopic hemostatic product, Nexpowder™ (Nexpowder™), received FDA approval for use in the prevention of lower gastrointestinal bleeding.

This approval recognizes the clinical efficacy and safety of Nexpowder for the prevention of lower gastrointestinal bleeding. Accordingly, the indications for Nexpowder have been expanded from the upper gastrointestinal tract to include the lower gastrointestinal tract.

Nexpowder is a powder-type therapeutic agent used to stop bleeding and prevent hemorrhage during endoscopy in cases of gastrointestinal bleeding. It enables quick and easy hemostasis even in emergency situations. It is the only product approved for the prevention of gastrointestinal bleeding in the United States, the world's largest medical device market.

A company representative stated, "'Nexpowder' has already been approved for use by the Korean Ministry of Food and Drug Safety (MFDS), the U.S. FDA (for the upper gastrointestinal tract), and the European CE-MDR, and is commercialized in domestic and international markets," adding, "With this additional indication approval, the scope of 'Nexpowder's' applications will expand further."